|
|
|
Are Herbal Remedies The Answer?
It seems that almost every day we come across a story in a newspaper or magazine which raises concerns about the use, misuse, or overuse of a particular pharmaceutical remedy in the treatment of minor ailments, or serious medical conditions. Often...
Fight Osteoporosis By Eating Foods With Vitamin K
We don’t hear about Vitamin K too often, but it is vital for good bone density as well as proper clotting of the blood. This is a fat soluble vitamin which is absorbed into the fat tissues and stored to be used by the body as needed. It is produced...
Stinky Animals
Oops, I meant to title this “Animal Instincts”. Oh, well – maybe that was one of those Freudian slip-ups. I dunno… We all are animals, right? Mammals? Sure we are. We all have fur, a self-regulating body temperature – and our females have...
That Brilliant Vitamin: Vitamin B
Perhaps you first read riboflavin at the back of a cereal box. Perhaps you first encountered folic acid from your first grade science teacher. Perhaps you first heard balanced diet from your mom. All that and more compose Vitamin B which is a group...
Three Natural Cures Your Kids Want You To Know!
Copyright 2005 Robert Fioravante
When Hippocrates said “the physician treats but nature heals,” he was describing the human body’s natural tendency toward minimizing illness and creating optimal health. As we know, however, the body needs a...
|
|
| |
|
|
|
|
|
|
Bextra Withdrawal Could Be Just the Beginning of Trouble for Pfizer
The pharmaceutical industry is a tremendously profitable one, as anyone who reads the business pages of their newspaper can see. Although it can take years to develop a new drug and bring it to market, the profits obtained from a breakthrough drug can be staggering. Last year Merck sold about $2.5 billion worth of Vioxx, and Pfizer sold about $1.3 billion worth of Bextra. The profits are huge, but so are the losses if a problem should develop with a pharmaceutical product. Pfizer voluntarily withdrew the popular anti-inflammatory drug Bextra from the market last month, and their stock has suffered from both the loss of sales and the potential for a large number of product liability lawsuits. Pfizer may have to endure a double whammy this year as the FDA announced that they are investigating reports that the impotence drug Viagra may be linked to cases of blindness in male users. Cialis and Levitra were also mentioned in the report, although most of the cases involved the use of Viagra.
The FDA reports shouldn’t cause alarm; the agency says that it is investigating fewer than 50 incidents of blindness in patients who use a drug that has been used by more than twenty million people since its introduction seven years ago. The FDA investigation says less about the likelihood of blindness in patients than it does about the agency’s own concerns about its reputation. The FDA rightly insists upon rigorous testing of drugs before they reach the market in the name of public safety. But that coin has two sides, and there are those who say that the agency is too quick to approve
potentially dangerous drugs and others who say that the agency’s testing isn’t thorough enough. Adding fuel to the fire are the recent memos obtained from Merck employees that suggest that the company was aggressively marketing Vioxx even though their sales staff knew the drug was potentially dangerous.
There may be no link between Viagra and blindness at all, as the form of sudden blindness alleged to have been caused by Viagra use is common to the sorts of patients who have erectile disfunction. The FDA is just being cautious, as they should be. Further tests will determine if there is an actual link. The party likely to suffer immediately is Pfizer, as stockholders, already concerned about Bextra lawsuits, drove the stock price lower immediately upon the release of the Viagra news. Sales will probably decrease, too, as patients who are now accustomed to reading about drugs being withdrawn from the market may shy away from the product until further tests are done. That could present a huge income for Pfizer, as they currently sell about $2 billion worth of Viagra each year. The drug business is a profitable one, but like any business, comes with risks. This year, it would seem that Pfizer is getting a double dose of bad medicine.
About the Author
©Copyright 2005 by Retro Marketing. Charles Essmeier is the owner of Retro Marketing, a firm devoted to informational Websites, including Bextra-Info.net, a site devoted to the withdrawn drug Bextra and StructuredSettlementHelp.com, a site devoted to structured settlements.
|
|
|
|
|
|
